Lance Berman
Private Equity Investor bei Ysios Capital Partners SGEIC SA
Profil
Lance Berman is currently a Venture Partner at Ysios Capital Partners SGEIC SA since 2018.
Prior to this, he worked as a Senior Medical Director at Pfizer Inc. from 2003 to 2009, a Principal at Schering-Plough Corp., a Clinical Research Associate at Janssen Pharmaceuticals, Inc., and as the Chief Medical Officer & Senior Vice President at CPEX Pharmaceuticals, Inc. from 2009 to 2011.
He also worked as the Chief Medical Officer & SVP-Commercial Strategy at Relypsa, Inc. in 2013.
Dr. Berman received his undergraduate and doctorate degrees from the University of Cape Town and his graduate degree from Hibernia College.
Aktive Positionen von Lance Berman
Unternehmen | Position | Beginn |
---|---|---|
Ysios Capital Partners SGEIC SA
Ysios Capital Partners SGEIC SA Investment ManagersFinance Ysios Capital Partners SGEIC SA (Ysios Capital) is a venture capital firm founded in 2007 by Joël Jean Pierre Jean-Mairet, Julia Salaverría Monfort and Josep Lluís Sanfeliu Benet. The firm is headquartered in San Sabastian, Spain with additional office in Barcelona. | Private Equity Investor | 01.05.2018 |
Ehemalige bekannte Positionen von Lance Berman
Unternehmen | Position | Ende |
---|---|---|
CPEX Pharmaceuticals, Inc.
CPEX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology CPEX Pharmaceuticals, Inc. is engaged in the development, licensing and commercialization of pharmaceutical products utilizing its validated drug delivery technology. Its technology enhances permeation and absorption of pharmaceutical molecules across the skin, nasal mucosa and eye through formulation development with proprietary molecules such as CPE-215. The company's first product is Testim, a gel for testosterone replacement therapy, which is a formulation of its technology with testosterone. Testim is licensed to Auxilium Pharmaceuticals, Inc., which is currently marketing it in the United States, Europe and other countries. Its other product is Nasulin, which is an intranasal formulation of insulin being developed to treat hyperglycemia in patients suffering from Type 1 and Type 2 diabetes. The company was founded on September 28, 2007 and is headquartered in Exeter, NH. | Technik-/Wissenschafts-/F&E-Leiter | 01.04.2011 |
PFIZER, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2009 |
Schering-Plough Corp.
Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Corporate Officer/Principal | - |
Janssen Pharmaceuticals, Inc.
Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. | Corporate Officer/Principal | - |
RELYPSA INC | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Lance Berman
University of Cape Town | Doctorate Degree |
Hibernia College | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
PFIZER, INC. | Health Technology |
Private Unternehmen | 5 |
---|---|
CPEX Pharmaceuticals, Inc.
CPEX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology CPEX Pharmaceuticals, Inc. is engaged in the development, licensing and commercialization of pharmaceutical products utilizing its validated drug delivery technology. Its technology enhances permeation and absorption of pharmaceutical molecules across the skin, nasal mucosa and eye through formulation development with proprietary molecules such as CPE-215. The company's first product is Testim, a gel for testosterone replacement therapy, which is a formulation of its technology with testosterone. Testim is licensed to Auxilium Pharmaceuticals, Inc., which is currently marketing it in the United States, Europe and other countries. Its other product is Nasulin, which is an intranasal formulation of insulin being developed to treat hyperglycemia in patients suffering from Type 1 and Type 2 diabetes. The company was founded on September 28, 2007 and is headquartered in Exeter, NH. | Health Technology |
Relypsa, Inc.
Relypsa, Inc. Pharmaceuticals: MajorHealth Technology Relypsa, Inc. operates as a bio-pharmaceutical company, which engages in the development and commercialization of late-stage medicines in the iron deficiency, nephrology, and cardio-renal therapeutic areas. It offers Veltassa, a potassium binder approved for the treatment of hyperkalemia. The company was founded by Jerry M. Buysse, Gerrit Klaerner, Michael Burdick, Jay P. Shepard, Detlef F. Albrecht, George Tyson, Sandra I. Coufal and Vic Ciaravino on October 29, 2007 and is headquartered in Redwood City, CA. | Health Technology |
Janssen Pharmaceuticals, Inc.
Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. | Health Technology |
Schering-Plough Corp.
Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Health Technology |
Ysios Capital Partners SGEIC SA
Ysios Capital Partners SGEIC SA Investment ManagersFinance Ysios Capital Partners SGEIC SA (Ysios Capital) is a venture capital firm founded in 2007 by Joël Jean Pierre Jean-Mairet, Julia Salaverría Monfort and Josep Lluís Sanfeliu Benet. The firm is headquartered in San Sabastian, Spain with additional office in Barcelona. | Finance |